Liquidia Co. (NASDAQ:LQDA) Receives Average Rating of “Buy” from Analysts

Liquidia Co. (NASDAQ:LQDA) has received a consensus rating of “Buy” from the nine research firms that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation, six have issued a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $26.63.

Several equities analysts have weighed in on the company. Needham & Company LLC restated a “buy” rating and set a $25.00 price objective on shares of Liquidia in a research note on Thursday, April 10th. HC Wainwright reiterated a “buy” rating and issued a $29.00 price objective on shares of Liquidia in a research report on Thursday, March 20th. Finally, Scotiabank reiterated an “outperform” rating on shares of Liquidia in a report on Thursday, March 20th.

Insider Buying and Selling at Liquidia

In other news, CEO Roger Jeffs sold 14,130 shares of the firm’s stock in a transaction on Monday, April 14th. The stock was sold at an average price of $13.57, for a total value of $191,744.10. Following the completion of the sale, the chief executive officer now owns 1,006,420 shares of the company’s stock, valued at $13,657,119.40. This trade represents a 1.38 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Rajeev Saggar sold 2,445 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $13.00, for a total transaction of $31,785.00. Following the sale, the insider now directly owns 267,943 shares in the company, valued at approximately $3,483,259. This represents a 0.90 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 33,123 shares of company stock valued at $448,366 in the last three months. Company insiders own 30.10% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of LQDA. SG Americas Securities LLC purchased a new position in Liquidia in the 1st quarter valued at $911,000. GAMMA Investing LLC boosted its stake in shares of Liquidia by 65.6% in the first quarter. GAMMA Investing LLC now owns 2,961 shares of the company’s stock valued at $44,000 after purchasing an additional 1,173 shares during the period. Rhumbline Advisers boosted its position in Liquidia by 6.0% in the 1st quarter. Rhumbline Advisers now owns 85,463 shares of the company’s stock valued at $1,261,000 after buying an additional 4,811 shares during the period. Whitcomb & Hess Inc. grew its stake in Liquidia by 85.3% during the 1st quarter. Whitcomb & Hess Inc. now owns 21,300 shares of the company’s stock worth $314,000 after purchasing an additional 9,805 shares in the last quarter. Finally, California State Teachers Retirement System grew its position in shares of Liquidia by 17.5% during the fourth quarter. California State Teachers Retirement System now owns 51,928 shares of the company’s stock worth $611,000 after buying an additional 7,725 shares in the last quarter. Institutional investors and hedge funds own 64.54% of the company’s stock.

Liquidia Price Performance

Shares of LQDA opened at $13.72 on Monday. The firm has a market capitalization of $1.17 billion, a PE ratio of -8.42 and a beta of 0.23. The company’s 50-day moving average is $14.65 and its 200-day moving average is $12.82. Liquidia has a fifty-two week low of $8.26 and a fifty-two week high of $16.81.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings data on Wednesday, March 19th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.08). Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%. The business had revenue of $2.92 million during the quarter, compared to analyst estimates of $4.60 million. Analysts predict that Liquidia will post -1.51 earnings per share for the current fiscal year.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).